Cross-Sector entity
FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Nicotine Patches, all published on March 17, 2026.
2 verified stories tracked
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Nicotine Patches, all published on March 17, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nicotine Patches. Shared-story counts are live from our verified record — not editorial picks.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A breakthrough comparative study has demonstrated that psychedelic-assisted therapy achieves significantly higher smoking cessation rates than traditional nicotine patches. This discovery suggests a major shift in addiction medicine, potentially disrupting the $25 billion global nicotine replacement therapy market.
Source: mainlinemedianews.com · orlandosentinel.com
